The E100: Extending runways, dumping drugs, factoring in a banking crisis and grappling with the IRA — there’s a lot for biotech execs to deal with

If there’s one major theme playing out in biotech this year, it’s watching out for the pitfalls. And then getting hit out of left field by something new and unexpected.

Bioregnum Opinion Column by John Carroll

For our H1 survey, I wanted to gauge...

Click to view original post